Virtus ETF Advisers’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-18,897
Closed -$1.61M 368
2020
Q3
$1.61M Buy
18,897
+1,592
+9% +$80.5K 0.84% 2
2020
Q2
$613K Sell
17,305
-92
-0.5% -$2.69K 0.29% 112
2020
Q1
$235K Sell
17,397
-2,528
-13% -$42.5K 0.1% 261
2019
Q4
$422K Sell
19,925
-523
-3% -$9.23K 0.07% 241
2019
Q3
$271K Sell
20,448
-1,139
-5% -$16.7K 0.05% 206
2019
Q2
$299K Buy
+21,587
New +$325K 0.06% 215
2019
Q1
Sell
-15,848
Closed -$226K 293
2018
Q4
$226K Sell
15,848
-3,818
-19% -$75.8K 0.04% 171
2018
Q3
$410K Sell
19,666
-14,095
-42% -$334K 0.04% 159
2018
Q2
$799K Sell
33,761
-26,601
-44% -$535K 0.71% 27
2018
Q1
$882K Buy
60,362
+32,166
+114% +$526K 0.77% 62
2017
Q4
$456K Sell
28,196
-14,588
-34% -$172K 0.57% 45
2017
Q3
$598K Buy
42,784
+3,913
+10% +$39K 0.08% 79
2017
Q2
$343K Sell
38,871
-36,163
-48% -$254K 0.05% 90
2017
Q1
$485K Buy
75,034
+7,193
+11% +$36.4K 0.09% 103
2016
Q4
$249K Sell
67,841
-13,169
-16% -$39K 0.07% 145
2016
Q3
$263K Hold
81,010
0.13% 119
2016
Q2
$188K Sell
81,010
-6,052
-7% -$20.2K 0.14% 139
2016
Q1
$218K Sell
87,062
-5,418
-6% -$12.2K 0.3% 73
2015
Q4
$284K Buy
+92,480
New +$258K 0.78% 43

Virtus ETF Advisers's IMMU Position: Q4 2020 in Review

Virtus ETF Advisers sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 18,897 shares — an estimated $1.61M sold.

Virtus ETF Advisers first reported a position in IMMU in Q4 2015 and held it in 19 quarters. The position peaked at $1.61M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Virtus ETF Advisers reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Virtus ETF Advisers sold 18,897 Immunomedics Inc shares in Q4 2020, an estimated $1.61M.
  • Virtus ETF Advisers first reported a position in Immunomedics Inc in Q4 2015 and held it in 19 quarters.
  • Virtus ETF Advisers's Immunomedics Inc position peaked at $1.61M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.